Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Total Debt (2018 - 2025)

Historic Total Debt for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $31.4 billion.

  • Takeda Pharmaceutical's Total Debt fell 975.46% to $31.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $31.4 billion, marking a year-over-year decrease of 975.46%. This contributed to the annual value of $29.7 billion for FY2025, which is 1170.76% down from last year.
  • Per Takeda Pharmaceutical's latest filing, its Total Debt stood at $31.4 billion for Q4 2025, which was down 975.46% from $33.2 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Total Debt high stood at $45.9 billion for Q1 2021, and its period low was $29.6 billion during Q1 2025.
  • For the 5-year period, Takeda Pharmaceutical's Total Debt averaged around $35.6 billion, with its median value being $34.3 billion (2022).
  • As far as peak fluctuations go, Takeda Pharmaceutical's Total Debt plummeted by 2425.72% in 2022, and later surged by 647.48% in 2024.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Total Debt stood at $41.3 billion in 2021, then fell by 24.26% to $31.3 billion in 2022, then rose by 4.61% to $32.7 billion in 2023, then increased by 6.47% to $34.8 billion in 2024, then dropped by 9.75% to $31.4 billion in 2025.
  • Its last three reported values are $31.4 billion in Q4 2025, $33.2 billion for Q3 2025, and $32.3 billion during Q2 2025.